The pathogenesis of multiple myeloma (MM), a neoplastic proliferation of monoclonal plasma cells, is a multi-step process with progressive acquisition of genetic aberrations. 1 Disease initiation involves the activation of oncogenes such as D-type cyclins by chromosomal translocations involving the immunoglobulin (Ig) gene. Inactivation of tumor suppressor genes, however, appears to be a late event.
1 Clinically, the disease may progress through monoclonal gammopathy of undetermined significance, smouldering myeloma, MM and plasma cell leukemia.
DNA methylation involves the addition of a methyl group to the carbon 5 position of the cytosine ring. Aberrant methylation in the CpG dinucleotide regions of gene promoters results in transcription repression, and may act as an alternative mechanism of gene inactivation. 2, 3 In myeloma, aberrant methylation is a frequent genetic alteration that results in perturbation of signaling pathways. 4, 5 For instance, we had shown previously that aberrant methylation of SHP1 was associated with absent SHP1 expression, resulting in constitutive activation of the Jak/ STAT pathway. Demethylation with 5-azacytidine led to re-expression of SHP1 and downregulation of Jak/STAT signalling, thus demonstrating that aberrant methylation was biologically relevant. 4 Several putative tumor suppressor genes such as SHP1 (targeting interleukin-6 (IL-6) signaling), DAP kinase (targeting p53-mediated apoptosis), CDKN2A (targeting the cell cycle) and E-CAD are frequently methylated in MM, and thus might be acquired during disease evolution. [4] [5] [6] [7] [8] Here, we describe the methylation status of multiple genes in four patients with MM, where disease evolution was punctuated by progressive gene hypermethylation.
Patients and methods
Serial bone marrow samples from four myeloma patients were studied for the presence of gene hypermethylation, which was correlated with the disease status and treatments at different time points. Patient 1 had a rapidly progressive clinical course after stable disease for about 10 months, which was associated with circulating plasma cells, massive increase in marrow plasmacytosis and serum paraprotein level. The change in these laboratory parameters was associated with sequential acquisition of hypermethylation E-CAD at the time of rapid progression, and additional CDKN2A and DAP kinase at the terminal stage.
Analysis of aberrant gene methylation
High molecular weight DNA was isolated by standard protocols from bone marrow aspirates. Methylation-specific polymerase chain reaction (MSP) of a panel of putative tumor suppressor genes including CDKN2A (alias p16), death-associated protein (DAP) kinase, E-cadherin (E-CAD), SHP1, p21, p27, p57, APC (adenomatous polyposis coli), Wif-1 (Wnt inhibitory factor-1), SOCS1 (suppressor of cytokine signalling-1) and caspase-8 was performed. The primers for the methylated (M-MSP) and unmethylated (U-MSP) promoter regions of genes were previously published.
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Result
Patient 1 is a 52-year-old woman with Durie-Salmon stage IIIA MM of IgA type. She achieved a partial response after four courses of VAD (vincristine, adriamycin and dexamethasone) ( Table 1) . She remained asymptomatic for 6 months with stable disease, (Figure 1a) , with a rapid upsurge of IgA about 13 months after diagnosis (Figure 1a ). Despite treatment with VCMP (vincristine, cyclophosphamide, melphalan and prednisolone) and bortezomib, the disease remained refractory with further rise of serum IgA (Figure 1a) . Moreover, there were circulating plasma cells despite pancytopenia, when marrow aspirate showed 80% plasma cells with distinct nucleolus and prominent intranuclear inclusions ( Figure 1b Moreover, to study if gene methylation might be acquired after exposure to combination chemotherapy, three additional myeloma patients with serial bone marrow samples during the course of illness were studied for the change of pattern of methylation of these four genes (Table 1) . Patient 2 developed a partial response to six courses of VAD but disease progressed shortly afterwards with marked increase in marrow plasmacytosis (75% plasmacytosis). Although none of these genes were methylated at diagnosis, marrow at 9 months at the point of disease progression showed methylation of CDKN2A, SHP1 and E-CAD. He achieved a major response to VCMP, which resulted in reduction of marrow plasma cells to 15%. He then received high-dose melphalan therapy with stem cell rescue from an HLA-identical sibling. Whereas CDKN2A, SHP1 and E-CAD were hypermethylated in the marrow at 9 months, only CDKN2A hypermethylation persisted at 28 and 50 months after high-dose melphalan. Subsequent marrow samples up to 65 months did not show acquisition of methylation of any of these genes. Patient 3 developed a partial response to VAD treatment and underwent autologous bone marrow transplantation 5 months after diagnosis, for which he received high-dose melphalan (200 mg/m 2 ). He had stable disease for prolonged period afterwards. Serial marrow samples from this patient showed absence of methylation of these genes up to 31 months after diagnosis. Patient 4 showed methylation of CDKN2A and E-CAD at diagnosis, which turned negative as disease was under control after prolonged melphalan, prednisolone treatment. However, he developed disease progression at 14 months with marrow plasmacytosis of 30%, when CDKN2A (but not E-CAD) hypermethylation re-appeared. He received high-dose Letters to the Editor melphalan and underwent autologous bone marrow transplantation. He had persistent disease for another 10 months. Apart from CDKN2A methylation, which was present at diagnosis, no additional methylation of other genes occurred despite repeated courses of chemotherapy.
Discussion
The clinical significance of aberrant gene methylation in MM was demonstrated in patient 1. After a period of stable disease, a sudden acceleration with a marked increase in tumor load (high paraprotein level and increase in marrow plasma cells) occurred. At this point, methylation of E-CAD was first detected. As E-CAD is an adhesion molecule and thus a metastasis suppressor, 9 hypermethylation of E-CAD might account for the presence of circulating plasma cells.
Moreover, to study if aberrant gene promoter methylation is gene specific, six additional genes including p21, p27, p57, APC, SOCS1 and caspase-8 were studied in the serial samples of patient 1 by MSP. None of the serial samples showed methylation of these additional genes, implying that methylation of SHP1, CDKN2A and E-CAD might indeed be biologically important, and not just part of an increased state of cellular methylating activity.
Furthermore, as patient 1 has received multiple regimens of combination chemotherapy during the course of disease, whether methylation in subsequent marrow samples was secondary to exposure of resistant plasma cells to these drugs or acquired naturally in resistant cell could not be distinguished. Currently, 5-azacytidine and decitabine are the major agents that may alter the cellular DNA methylation status by inhibition of DNA methyltransferase. Although there are no data to show that chemotherapy may alter the methylation status of cancer cells, this cannot be excluded. Therefore, we studied the pattern of change in methylation of this four genes in three additional patients who had serial marrow samples (Table 1) . Patient 2 acquired methylation of CDKN2A, SHP1 and E-CAD 9 months after diagnosis, when he developed rapid disease progression with marked increase in plasmacytosis (Table 1) . This was consistent with acquisition of gene methylation during clonal evolution, manifesting as clinical disease progression. Interestingly, whereas CDKN2A, SHP1 and E-CAD were hypermethylated in the marrow at 9 months, only CDKN2A hypermethylation persisted at 28 and 50 months after highdose melphalan. This might suggest the presence of two clones of myeloma cells at 9 months after diagnosis, one harboring CDKN2A hypermethylation and the other harboring concomitant SHP1 and E-CAD hypermethylation, which was more rapidly eradicated by high-dose melphalan than the one with CDKN2A hypermethylation. This notion of separate tumor clones was further illustrated by the methylation pattern in patient 4, which showed concomitant hypermethylation of both CDKN2A and E-CAD at diagnosis, but only the clone with CDKN2A but not E-CAD hypermethylation persisted during subsequent disease evolution, consistent with the rapid eradication of E-CAD-methylated but not the CDKN2A-methylated clone after initial chemotherapy. Moreover, the more rapid eradication of the clone harboring E-CAD hypermethylation with chemotherapy in patients 2 and 4 is interesting. On the other hand, in patient 2, additional methylation of genes was not acquired during the course of illness despite repeated courses of Table 1 Patients with serial BM samples, who were treated with repeated courses of different combination chemotherapy
Allo-BMT Melphalan (140 mg/m 2 )/TBI 15
Abbreviations: ABMT, autologous bone marrow transplantation; allo-BMT, allogeneic bone marrow transplantation; BM, bone marrow aspiration; BMT, bone marrow transplantation; DAP-K, DAP kinase; E-CAD, E-cadherin; MP, melphalan, prednisolone; TBI, total body irradiation; VAD, vincristine, adriamycin, dexamethasone; VCMP, vincristine, cyclophosphamide, melphalan, prednisolone; +, presence of methylation; À, absence of methylation. Bold represents: Disease progression with a marked increase in marrow plasmacytosis.
chemotherapy including high-dose therapy. Lastly, DAP kinase was not hypermethylated in patients 2-4, and remained unmethylated throughout their clinical course despite multiple chemotherapy regimens. In summary, our data suggested that methylation of genes might be acquired during disease progression but not after repeated courses of chemotherapy. Moreover, although conventional views of tumor progression involve accretion of genetic mutations, the clinical course of patient 1 showed that cumulative epigenetic alterations might also play significant roles. Furthermore, multiple tumor clones might be present. Methylation of E-CAD appeared in S3. Methylation of CDKN2A and DAP Kinase (DAPK) occurred only in S4. MW: molecular weight control; N1 and N2: normal marrow DNA; S1-S4: four marrow samples of the patient corresponding to the time points shown in ; P1 and P2: two positive controls of methylated DNA. (d) Methylated-methylation-specific polymerase chain reaction (M-MSP) study of additional genes in the serial samples (S1-S4). None of the samples showed methylation of p21, p57, Wnt inhibitory factor-1 (Wif-1) and adenomatous polyposis coli (APC). B: reagent blank; N1-N4: normal marrow DNA; S1-S4: four marrow samples of the patient corresponding to the time points shown in P: methylated-positive control DNA. DNA integrity was demonstrated by positive amplification in normal and marrow DNA by unmethylatedmethylation-specific polymerase chain reaction (U-MSP).
